WO2006083841A3 - Therapeutic esters - Google Patents

Therapeutic esters Download PDF

Info

Publication number
WO2006083841A3
WO2006083841A3 PCT/US2006/003363 US2006003363W WO2006083841A3 WO 2006083841 A3 WO2006083841 A3 WO 2006083841A3 US 2006003363 W US2006003363 W US 2006003363W WO 2006083841 A3 WO2006083841 A3 WO 2006083841A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic esters
therapeutic
esters
prodrug
compound
Prior art date
Application number
PCT/US2006/003363
Other languages
French (fr)
Other versions
WO2006083841A2 (en
Inventor
David F Woodward
Robert M Burk
Original Assignee
Allergan Inc
David F Woodward
Robert M Burk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, David F Woodward, Robert M Burk filed Critical Allergan Inc
Priority to US11/814,815 priority Critical patent/US7868035B2/en
Publication of WO2006083841A2 publication Critical patent/WO2006083841A2/en
Publication of WO2006083841A3 publication Critical patent/WO2006083841A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

A compound comprising Formula (I) or a pharmaceutically acceptable salt or a prodrug thereof; wherein X and Y are described herein.
PCT/US2006/003363 2005-02-01 2006-01-31 Therapeutic esters WO2006083841A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/814,815 US7868035B2 (en) 2005-02-01 2006-01-31 Therapeutic esters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64937805P 2005-02-01 2005-02-01
US60/649,378 2005-02-01

Publications (2)

Publication Number Publication Date
WO2006083841A2 WO2006083841A2 (en) 2006-08-10
WO2006083841A3 true WO2006083841A3 (en) 2006-10-19

Family

ID=36608760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/003363 WO2006083841A2 (en) 2005-02-01 2006-01-31 Therapeutic esters

Country Status (2)

Country Link
US (1) US7868035B2 (en)
WO (1) WO2006083841A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648213B2 (en) * 2004-10-06 2014-02-11 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
ES2466346T3 (en) * 2006-10-02 2014-06-10 Techfields Biochem Co. Ltd Prodrugs of water soluble prostaglandins with positive charge and compounds related to very high skin penetration rates
WO2009132093A2 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7981887B2 (en) 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
AU2014212275B2 (en) 2013-02-01 2018-09-06 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (en) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Aqueous ophthalmic solutions of phentolamine and its medical applications
JP6030168B2 (en) * 2015-03-09 2016-11-24 テックフィールズ バイオケム カンパニー リミテッド Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin permeability
MX2021004708A (en) 2018-10-26 2021-11-03 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders.
CN115368310A (en) 2021-05-18 2022-11-22 奥库菲尔医药公司 Method for synthesizing phentolamine mesylate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1136326B (en) * 1959-11-11 1962-09-13 Lab Rotenburg Process for the production of 9-heptadecinic acid, 9-pentadecinic acid and their salts with physiologically compatible bases
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US20020198249A1 (en) * 1992-09-21 2002-12-26 Burk Robert M. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
JP2005272413A (en) * 2004-03-26 2005-10-06 Ichimaru Pharcos Co Ltd New 3-hydroxyanthranilic acid derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1136326B (en) * 1959-11-11 1962-09-13 Lab Rotenburg Process for the production of 9-heptadecinic acid, 9-pentadecinic acid and their salts with physiologically compatible bases
US20020198249A1 (en) * 1992-09-21 2002-12-26 Burk Robert M. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
JP2005272413A (en) * 2004-03-26 2005-10-06 Ichimaru Pharcos Co Ltd New 3-hydroxyanthranilic acid derivative

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A. ZAMYATINA ET AL.: "Synthesis and purity assessment of tetra- and pantaacyl lipid A of Chlamydia containing (R)-3-hydroxyicosanoic acid", TETRAHEDRON, vol. 60, 2004, Elsevier, pages 12113 - 12137, XP002389438 *
C. BOGA ET AL.: "Fluorescein conjugates of 9- and 10-hydroxystearic acids: synthetic strategies, photophysical characterization, and confocal microscopy applications", ANALYTICAL BIOCHEMISTRY., vol. 335, 2004, US; ACADEMIC PRESS INC. NEW YORK., pages 196 - 209, XP002389439 *
D. CHAPMAN ET AL.: "The physical properties of phospholipids. I. SOlid state and mesomorphic properties of some 2,3-diacyl-DL-phosphatidylethanolamines", PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON. SERIES A, MATHEMATICAL AND PHYSICAL SCIENCES., vol. 290, no. 1420, 1966, GB; ROYAL SOCIETY OF LONDON, LONDON., pages 115 - 142 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1946, XP002389449, retrieved from STN Database accession no. 1947:11301 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1955, XP002389448, retrieved from STN Database accession no. 1955:84618 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1966, XP002389447, retrieved from STN Database accession no. 1966:35271 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002389446, retrieved from STN Database accession no. 2005:306624 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2005, XP002389445, retrieved from STN Database accession no. 2005:1073960 *
E GONICK ET AL.: "Association in solutions of colloidal electrolytes; hexanolamine elaidate and trihydroxystearate", RECUEIL DES TRAVAUX CHIMIQUES DE PAYS-BAS ET DE LA BELGIQUE., no. 65, 1946, NL, pages 601 - 605 *
H. MASAMUNE ET AL.: "Synthesis of artificial group A and B substances", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE., no. 61, 1955, JP; TOHOKU UNIVERSITY MEDICAL PRESS, SENDAI., pages 283 - 301 *
L. LIU ET AL.: "Primary studies on synthesis of Uperzine A linoleic acid ester and its characteristics", ZHONGCAOYAO - CHINESE TRADITIONAL AND HERBAL DRUGS, vol. 35, no. 3, 2004, CN; ZHONGEAOYA ZAZHI BIANJIBU, pages 253 - 255 *

Also Published As

Publication number Publication date
US7868035B2 (en) 2011-01-11
US20090012145A1 (en) 2009-01-08
WO2006083841A2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2006083841A3 (en) Therapeutic esters
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
HUS000502I2 (en) Opicapone or a pharmaceutically acceptable salt thereof
TW200740758A (en) Benzoquinazoline derivatives
WO2007117465A3 (en) Indazole compounds
WO2005077932A3 (en) Chemokine receptor antagonists
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2007084728A3 (en) 2-imino-benzimidazoles
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2008005542A3 (en) Antiviral phosphinate compounds
IL205354A0 (en) Spiroindolinone derivatives
EP1790638A4 (en) Carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2007135527A3 (en) Benzimidazolyl compounds
WO2005089718A3 (en) Pharmaceutical compositions
TNSN06220A1 (en) Benzimidazole derivatives
ZA200708811B (en) Use of a sulfonamide compound for improving the pharma-cokinetics of a drug
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
MX2009003081A (en) Pyrrole derivatives useful for the treatment of cytokine-mediated diseases.
WO2009064374A8 (en) Oral formulations of bis(thiohydrazide amides)
WO2007112913A3 (en) Benzimidazole derivatives
DK1814848T3 (en) 2,3,4-substituted-cyclopentanones as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06719960

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11814815

Country of ref document: US